Drug
AZD3241 clinical trials
Also written Verdiperstat, AZD3241 and BHV-3241.
- studies test it
- 10
- open now
- 0
- in phase 3
- 3
- first study started
- 2008
How studies write it
Studies that test it under each name
Other names
Studies by the year they started
10 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
AstraZeneca (5) · Merit E. Cudkowicz, MD (2) · Peter Ljubenkov, MD (1) · Biohaven Pharmaceuticals, Inc. (1) · Brigham and Women's Hospital (1)
Often tested with
Tested in the same studies.
Zilucoplan (1) · CNM-Au8 (1) · Pridopidine (1) · SLS-005 (1) · Fosigotifator sodium tromethamine (1) · Fosigotifator (1) · Evetifator (1) · NUZ-001 (1)
Studies
Open first, then newest update. How each study uses AZD3241 is read from its arms, and is right about nine times in ten.
Testing it · 10
- HEALEY ALS Platform Trial - Master ProtocolActive, not recruitingPhase 2/3Merit E. Cudkowicz, MDNCT04297683Written as Verdiperstat
- Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 PathologyActive, not recruitingPhase 1Peter Ljubenkov, MDNCT05184569Written as Verdiperstat
- Study of BHV-3241 in Participants With Multiple System AtrophyCompletedPhase 3Biohaven Pharmaceuticals, Inc.NCT03952806Written as Verdiperstat
- HEALEY ALS Platform Trial - Regimen B VerdiperstatCompletedPhase 2/3Merit E. Cudkowicz, MDNCT04436510Written as Verdiperstat
- Effect of Verdiperstat on Microglial Activation in Well-characterized MSA PatientsCompletedEarly Phase 1Brigham and Women's HospitalNCT04616456Written as Verdiperstat
- AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA PatientsCompletedPhase 2AstraZenecaNCT02388295Written as AZD3241
- A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's DiseaseCompletedPhase 2AstraZenecaNCT01603069Written as AZD3241 300 mg BID
- To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy VolunteersCompletedPhase 1AstraZenecaNCT01457807Written as AZD3241 ER formulation 1
- Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241CompletedPhase 1AstraZenecaNCT00914303Written as AZD3241
- Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy VolunteersCompletedPhase 1AstraZenecaNCT00729443Written as AZD3241